A review of more than 50 PDRN technologies and finished products has found marine DNA, recombinant sequences, bacterial fermentation, microalgae and plant-derived nucleic acids all carrying the same four letters — despite not being biologically interchangeable. That finding sits at the centre of the debate over 2026's most talked-about skin care ingredient, as PDRN moves rapidly from regenerative medicine into serums, creams, masks and scalp treatments.

"One of the first questions I ask when a new ingredient or formulation lands on my desk featuring PDRN on the label is, 'Is this real PDRN?'" writes a cosmetic scientist with more than 16 years in formulation and ingredient evaluation, who conducted the review.

The answer matters because PDRN — polydeoxyribonucleotide — is a specific material: a mixture of purified DNA fragments traditionally obtained from salmon or trout reproductive tissue. Under the label, sources vary widely.

What does PDRN actually do?

PDRN does not rewrite human DNA. Its proposed activity involves two pathways:

• The adenosine A2A receptor, associated with inflammatory regulation and repair signalling
• The salvage pathway, through which stressed cells reuse nucleotides for DNA synthesis

"I think of PDRN less as giving skin a new instruction manual and more as supplying some of the vocabulary and raw materials required for repair," the scientist writes.

Much of PDRN's scientific reputation comes from pharmaceutical research involving injections or compromised tissue — conditions very different from a cosmetic serum applied to intact skin. That distinction shapes how much of the injectable evidence can be transferred to topical claims.

Why the delivery question changes everything

"The moment PDRN enters a cosmetic serum, the question changes," the review notes. Large DNA fragments face well-documented challenges crossing the stratum corneum, so a mechanism proven through injection does not automatically translate into a proven topical benefit. The reviewer describes PDRN as "fascinating" precisely because it connects molecular biology with cosmetic formulation while exposing the distance between an exciting mechanism and a demonstrated result on healthy skin.

For formulators and buyers, the practical implications are:

• Verify the origin of the PDRN listed on a label — salmon-derived, recombinant, fermentation, microalgae and plant-derived nucleic acids are not equivalent materials
• Distinguish injectable-grade evidence from topical evidence when reviewing supplier claims
• Treat mechanistic plausibility through the A2A receptor and salvage pathway as a starting point, not proof of efficacy in a finished serum

How large is the evidence gap?

The review's core observation is structural. PDRN earned its reputation in regenerative medicine, where it was delivered to compromised tissue under pharmaceutical conditions. Cosmetics use it on healthy skin, through a topical route, at formulation-dependent concentrations and fragment sizes. Each variable moves the ingredient further from the studies that made it famous.

The reviewer's position is not dismissive. With 16 years in ingredient evaluation, they call PDRN an ingredient worth studying — one that legitimately bridges molecular biology and formulation science. But the burden of proof sits with finished products, not with the underlying pharmacology, and the wide variance in what "PDRN" means across 50+ reviewed technologies suggests the label alone tells a professional very little.

As PDRN continues its spread from clinics into the mass skin care and scalp treatment market, expect scrutiny to shift from whether the ingredient is exciting — it is — to whether each specific product contains the real material at meaningful levels and can show topical results.